Cost-effectiveness of diabetes pay-for-performance incentive designs

Medical Care

Volumn 53, Issue 2, 2015, Pages 106-115

  Hsieh, Hui Min ^a   Tsai, Shu Ling ^b   Shin, Shyi Jang ^a   Mau, Lih Wen ^c   Chiu, Herng Chia ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b Ministry of Health and Welfare   (Taiwan)

^c National Marrow Donor Organization   (United States)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

costeffectiveness analysis (CEA); Diabetes pay for performance; incentive designs; incremental cost effectiveness ratios (ICERs); quality adjusted life years (QALYs)

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL FEE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PAY FOR PERFORMANCE INCENTIVE; PRIORITY JOURNAL; PROGRAM EFFECTIVENESS; PROPENSITY SCORE; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; QUASI EXPERIMENTAL STUDY; REFERENCE DATABASE; REIMBURSEMENT; TAIWAN; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; ECONOMICS; HEALTH CARE COST; HEALTH CARE QUALITY; PUBLIC HEALTH; STATISTICS AND NUMERICAL DATA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; PROCESS ASSESSMENT (HEALTH CARE); REIMBURSEMENT, INCENTIVE; TAIWAN;

EID: 84922105303     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000264     Document Type: Article

References (43)

1. Petersen LA, Woodard LD, Urech T, et al. Does pay-for-performance improve the quality of health care? Ann Int Med. 2006;145:265-272.
2. Berenson R, Pronovost PJ, Krumholz HM. Achieving the potiential of health care performance measures. Timely Analysis of Inmediate Health Policy Issues. 2013. Available at: http://www.urban.org/UploadedPDF/412823-Achieving-the-Potential-of-Health-Care-Performance-Measures. pdf?RSSFeed = UI-HealthPolicyCenter.xml. Accessed March 3, 2014.
3. Blumenthal D, Dixon J. Health-care reforms in the USA and England: areas for useful learning. Lancet. 2012;380:1352-1357.
4. Korda H, Eldridge GN. Payment incentives and integrated care delivery: levers for health system reform and cost containment. Inquiry. 2011;48:277-287.
5. Ryan AM, FDamberg CL. What can the past of pay-for-performance tell us about the future of value-based purchasing in Medicare? Healthcare. 2013;1:42-49.
6. White J. Cost Control after the ACA. Public Administration Review. 2013. Available at: http://policy.case.edu/CostControlAftertheACA.pdf. Accessed March 4, 2014.
7. Chung KC, Shauver MJ. Measuring quality in health care and its implications for pay-for-performance initiatives. Hand Clin. 2009;25: 71-81.
8. de Bruin SR, Baan CA, Struijs JN. Pay-for-performance in disease management: a systematic review of the literature. BMC Health Serv Res. 2011;11:272.
9. Van Herck P, De Smedt D, Annemans L, et al. Systematic review: effects, design choices, and context of pay-for-performance in health care. BMC Health Serv Res. 2010;10:247.
10. Eijkenaar F. Key issues in the design of pay for performance programs. Eur J Health Econ. 2013;14:117-131.
11. Shih T, Nicholas LH, Thumma JR, et al. Does pay-for-performance improve surgical outcomes? An evaluation of phase 2 of the premier hospital quality incentive demonstration. Ann Surg. 2014;259: 677-681.
12. Eijkenaar F, Emmert M, Scheppach M, et al. Effects of pay for performance in health care: a systematic review of systematic reviews. Health Policy. 2013;110:115-130.
13. Mehrotra A, Sorbero ME, Damberg CL. Using the lessons of behavioral economics to design more effective pay-for-performance programs. Am J Manag Care. 2010;16:497-503.
14. Emmert M, Eijkenaar F, Kemter H, et al. Economic evaluation of payfor-performance in health care: a systematic review. Eur J Health Econ. 2012;13:755-767.
15. Gillam SJ, Siriwardena AN, Steel N. Pay-for-performance in the United Kingdom: impact of the quality and outcomes framework: a systematic review. Ann Fam Med. 2012;10:461-468.
16. Meacock R, Kristensen SR, Sutton M. The cost-effectiveness of using financial incentives to improve provider quality: a framework and application. Health Econ. 2014;23:1-13.
17. Nahra TA, Reiter KL, Hirth RA, et al. Cost-effectiveness of hospital pay-for-performance incentives. Med Care Res Rev. 2006;63(suppl): 49S-72S.
18. Tan EC, Pwu RF, Chen DR, et al. Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan? Qual Life Res. 2014;23:689-698.
19. Jiang YD, Chang CH, Tai TY, et al. Incidence and prevalence rates of diabetes mellitus in Taiwan: analysis of the 2000-2009 Nationwide Health Insurance database. J Formos Med Assoc. 2012;111: 599-604.
20. Administration NHI. Annual statistical report for National Health Insurance. 2011. Available at: http://www.nhi.gov.tw. Accessed February 21, 2014.
21. Chen TT, Chung KP, Lin I, et al. The unintended consequence of diabetes mellitus pay-for-performance (p4p) program in Taiwan: are patients with more comorbidities or more severe conditions likely to be excluded from the P4P program? Health Serv Res. 2011;46(1p1): 47-60.
22. Lee TT, Cheng SH, Chen CC, et al. A pay-for-performance program for diabetes care in Taiwan: a preliminary assessment. Am J Manag Care. 2010;16:65-69.
23. Chen PC, Lee YC, Kuo RN. Differences in patient reports on the quality of care in a diabetes pay-for-performance program between 1 year enrolled and newly enrolled patients. Int J Qual Health Care. 2012;24:189-196.
24. Cheng SH, Lee TT, Chen CC. A longitudinal examination of a pay-forperformance program for diabetes care: evidence from a natural experiment. Med Care. 2012;50:109-116.
25. Pham HH, Schrag D, O'Malley AS, et al. Care patterns in Medicare and their implications for pay for performance. N Engl J Med. 2007;356: 1130-1139.
26. Young BA, Lin E, Von Korff M, et al. Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization. Am J Manag Care. 2008;14:15-23.
27. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
28. Meduru P, Helmer D, Rajan M, et al. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22(suppl 3):408-418.
29. Dehejia RH, Wahba S. Propensity score-matching methods for nonexperimental causal studies. Rev Econ Stat. 2002;84:151-161.
30. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med. 2008;27: 2037-2049.
31. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-1589.
32. Brazier JE, Roberts J. The estimation of a preference-based measure of health from the SF-12. Med Care. 2004;42:851-859.
33. Pickard AS, Wang Z, Walton SM, et al. Are decisions using cost-utility analyses robust to choice of SF-36/SF-12 preference-based algorithm? Health Qual Life Outcomes. 2005;3:11.
34. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
35. Gold MR, Siegel JE, Russel LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
36. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the Economic Evaluation of Health Care Programmes. Oxford, United Kindom: Oxford University Press; 1987.
37. Weintraub WS, Cohen DJ. The limits of cost-effectiveness analysis. Circulation. 2009;2:55-58.
38. Cromwell J, Smith KW. Evaluating pay for performace interventions. In: Cromwell J, Trisolini MG, Pope GC, Mitchell JB, Greenwald LM, eds. Pay for Performance in Health Care: Methods and Approaches. Research Triangle Park, NC: RTI Press; 2011. Available at: http://www.rti.org/rtipress. Accessed May 15, 2013.
39. Campbell SM, Reeves D, Kontopantelis E, et al. Effects of pay for performance on the quality of primary care in England. N Engl J Med. 2009;361:368-378.
40. Vaghela P, Ashworth M, Schofield P, et al. Population intermediate outcomes of diabetes under pay-for-performance incentives in England from 2004 to 2008. Diabetes Care. 2009;32:427-429.
41. Curtin K, Beckman H, Pankow G, et al. Return on investment in pay for performance: a diabetes case study. J Healthc Manag. 2006;51: 365-374; discussion 375-366.
42. Chang RE, Lin SP, Aron DC. A pay-for-performance program in Taiwan improved care for some diabetes patients, but doctors may have excluded sicker ones. Health Aff. 2012;31:93-102.
43. Glasziou P, Alexander J, Beller E, et al. Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial. Health Qual Life Outcomes. 2007;5:21.